Drugs & Targets FDA approves Opdualag for unresectable or metastatic melanoma March 25, 2022Vol.48 No.12
Drugs & Targets FDA approves Pluvicto for metastatic castration-resistant prostate cancer March 25, 2022Vol.48 No.12
Drugs & Targets FDA approves Opdivo and platinum-doublet chemotherapy for early-stage NSCLC March 11, 2022Vol.48 No.10
Drugs & Targets FDA grants priority review to Tibsovo in combination with azacitidine in previously untreated IDH1-mutated AML March 11, 2022Vol.48 No.10
Drugs & Targets FDA clinical trial guidances touch on Biden administration’s goals for advancing development of cancer treatments March 11, 2022Vol.48 No.10
Drugs & Targets Six months after court-ordered deadline, FDA hasn’t ruled on major e-cigarette manufacturers’ product applications, advocates say March 11, 2022Vol.48 No.10
Drugs & Targets FDA grants Fast Track designation to IO-202, anti-LILRB4 myeloid checkpoint inhibitor for AML February 18, 2022Vol.48 No.07
Regulatory News In a 14:1 vote, ODAC nixes a PD-1 drug developed in China; data not generalizable to U.S. population February 11, 2022Vol.48 No.06By Paul Goldberg and Alice Tracey
Conversation with The Cancer LetterRegulatory News FDA says it had no input as companies developed checkpoint inhibitors in China February 04, 2022Vol.48 No.05By Paul Goldberg
